Atea Pharmaceuticals (AVIR) Earnings Analysis

Atea Pharmaceuticals (AVIR) has no confirmed upcoming earnings date. Last quarter (2026-03-05) it missed with EPS -0.57 USD vs -0.49 USD est (-16.3%). It has beaten estimates in 1/3 recent quarters (33%). Trailing P/E -2.28.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does AVIR next report earnings?

No confirmed upcoming earnings date is currently scheduled for AVIR. This page updates as the calendar is published.

AVIR earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-05-0.57 USD-0.49 USD-16.3%Miss
2025-05-12-0.4 USD-0.56 USD+28.6%Beat
2025-03-06-0.4 USD-0.35 USD-14.3%Miss

Beat rate: 1/3 (33%) over reported quarters with consensus data.

AVIR valuation and analyst view

Trailing P/E-2.28
Trailing EPS-2.14041 USD
Price / book1.63
Dividend yield0.00%
Market cap0.38B
Analyst consensusHold (1 buy / 2 hold / 1 sell)
Avg price target10 USD

Related research pages

Frequently asked questions

When is Atea Pharmaceuticals (AVIR)'s next earnings date?

No confirmed upcoming earnings date is currently scheduled for AVIR. This page updates as the calendar is published.

Did AVIR beat earnings last quarter?

In its 2026-03-05 report, AVIR posted EPS of -0.57 USD versus a -0.49 USD estimate — a miss of 16.3%.

What is AVIR's earnings track record?

Over the last 3 reported quarters with consensus data, AVIR beat estimates 1 times (33%).

What is AVIR's current P/E ratio and EPS?

AVIR trades at a trailing P/E of -2.28 on trailing EPS of -2.1404146993030295 USD.

What do analysts rate AVIR?

Analyst consensus is "Hold" across 4 ratings (0 strong buy, 1 buy, 2 hold, 1 sell, 0 strong sell). Average 12-month price target: 10 USD.